Merck notes HDL cholesterol benefits of drug candidate

10/4/2007 | Star-Ledger (Newark, N.J.), The · Bloomberg1

Merck's experimental treatment anacetrapib significantly increased "good" HDL cholesterol levels in patients and lowered "bad" LDL cholesterol levels without boosting blood pressure, according to a company study. Experts compare anacetrapib to Pfizer's anticholesterol drug torcetrapib, which failed to control blood pressure in trials.

View Full Article in:

Star-Ledger (Newark, N.J.), The · Bloomberg1

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN